Search

The impact of anti-COVID-19 vaccination was also assessed in CLL patients receiving therapy at the time of anti-COVID-19 vaccination ( I n i = 948 or 64.0%). According to our results, CLL treatment worsened the defective response to vaccination observed in CLL patients. Keywords: chronic lymphocytic leukemia; meta-analysis; mRNA SARS-CoV-2 vaccine; systematic review; treatment status EN chronic lymphocytic leukemia meta-analysis mRNA SARS-CoV-2 vaccine systematic review treatment status 264 267 4 02/09/22 20220301 NES 220301 ACKNOWLEDGMENTS None. Information on the type of therapy at the time of vaccination was available for 779 patients and allowed patients' stratification in four different therapeutic groups; Patients who had been given an anti-CD20 monoclonal antibody at any time before vaccination ( I n i = 254). [Extracted from the article]

Bortezomib is a potent and selective proteasome inhibitor recently introduced in the treatment of multiple myeloma (MM). This drug produces significant responses in about one-third of patients with relapsed/refractory disease. We first recognized the lack of efficacy of thalidomide in soft-tissue plasmacytomas. There is little information on the effect of bortezomib on extramedullary myeloma. Four of 23 patients treated with bortezomib at our institution had extramedullary involvement at the time of relapse. In three of these patients large soft-tissue plasmacytomas disappeared. This indicates that bortezomib may be useful in clinical situations of extramedullary disease in which other agents, such as thalidomide, may not be effective. [ABSTRACT FROM AUTHOR]